Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $8.14 Average Price Target from Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have received an average recommendation of “Hold” from the twelve analysts that are presently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $8.1250.

Several equities analysts have weighed in on NMRA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Wednesday, October 8th. Royal Bank Of Canada upgraded shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $4.00 to $7.00 in a report on Monday, December 1st. Stifel Nicolaus upped their target price on shares of Neumora Therapeutics from $2.00 to $3.00 and gave the stock a “hold” rating in a research note on Monday, November 17th. Mizuho set a $6.00 price target on shares of Neumora Therapeutics in a research report on Monday, January 5th. Finally, Leerink Partners started coverage on shares of Neumora Therapeutics in a research note on Monday. They issued an “outperform” rating and a $8.00 price target for the company.

Neumora Therapeutics Stock Performance

Shares of NMRA stock opened at $2.15 on Monday. The firm has a market cap of $359.24 million, a P/E ratio of -1.46 and a beta of 3.22. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85. Neumora Therapeutics has a one year low of $0.61 and a one year high of $3.25. The firm’s 50 day moving average price is $2.16 and its 200-day moving average price is $1.90.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). As a group, equities research analysts predict that Neumora Therapeutics will post -1.61 EPS for the current year.

Insider Activity

In other news, insider Daljit Singh Aurora sold 114,703 shares of Neumora Therapeutics stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $2.68, for a total value of $307,404.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kristina Burow bought 1,915,700 shares of the business’s stock in a transaction that occurred on Monday, October 27th. The shares were purchased at an average price of $2.61 per share, for a total transaction of $4,999,977.00. Following the completion of the purchase, the director directly owned 6,046,907 shares of the company’s stock, valued at approximately $15,782,427.27. This trade represents a 46.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 26.80% of the company’s stock.

Hedge Funds Weigh In On Neumora Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of NMRA. Legacy Private Trust Co. acquired a new position in shares of Neumora Therapeutics during the 3rd quarter worth about $25,000. CWM LLC lifted its stake in Neumora Therapeutics by 41.8% during the second quarter. CWM LLC now owns 35,750 shares of the company’s stock worth $26,000 after purchasing an additional 10,537 shares during the last quarter. Catalyst Funds Management Pty Ltd acquired a new position in Neumora Therapeutics in the second quarter valued at approximately $29,000. Virtu Financial LLC acquired a new position in Neumora Therapeutics in the third quarter valued at approximately $31,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Neumora Therapeutics in the second quarter valued at approximately $41,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.